

ASTRIA CONNECTION

Issue #2 | February 2022

Reflecting on 2021 and Looking Ahead to 2022

A LETTER FROM CEO JILL MILNE

At the start of a new year, I like to take the opportunity to both reflect and look ahead. While 2021 continued to test us individually and collectively, it was also a year where the life science community responded to historic challenges and demonstrated our collective resilience, adaptability, creativity, and strength of common purpose. I am proud of our team at Astria for embodying these qualities.

Our mission is clear: we are dedicated to bringing life-changing therapies to patients and families impacted by hereditary angioedema (HAE) and rare and niche allergic and immunological diseases.

With our lead candidate, [STAR-0215](#), we are working to reduce the treatment burden for people living with HAE by developing a therapy with the potential to be dosed once every 3 months or longer. We are driven to change the way that patients live with HAE by allowing them to focus their time and energy on what matters most to them. Their [stories](#) inspire us every day and remind us of the critical importance of our work.

Our progress in 2021 has energized our team at Astria and we are looking forward to 2022. We are on track to file an Investigational New Drug application for STAR-0215 in mid-2022, and we plan to initiate a Phase 1 clinical trial shortly thereafter with initial results anticipated by year end 2022.

As we turn the page to a new year, I am both grateful and inspired to know that our team will continue in our commitment to benefit patients, work to address their needs, and improve their quality of life. Read some of our 2022 commitments to the HAE community throughout this newsletter.



Jill Milne, Ph.D., Chief Executive Officer
Astria Therapeutics

"I resolve to work every day to advance STAR-0215 as though HAE ran in my own family."

- Noah Clauser, CFO

"I'm committed to deepening my knowledge of HAE and the people impacted by HAE."

- Jessica Lazaro,
Executive Assistant

"I am dedicated to doing my best work on STAR-0215 to bring an effective prophylactic treatment to the HAE community to improve quality of life."

- Therese Ton,
R&D Program Coordinator

Rare Disease Day 2022

Rare Disease Day on February 28th works towards equity in social opportunity, healthcare, and access to diagnosis and therapies for people living with a rare disease. As members of the HAE community, our goal is to learn from the voices of people living with HAE and other rare diseases, understand their challenges, and develop therapies that can make a meaningful difference in their lives.

You can learn more about upcoming events around Rare Disease Day here: <https://rarediseases.org/rare-disease-day/rare-disease-day-events/>

"I am committed to continue learning from the HAE community and applying that knowledge towards the development of a preventative therapy that optimally addresses patients' unmet needs."

- Joe Pirrello, Executive Director,
Business Development



Stay in touch!

Sign up to join our community and receive our newsletters in your inbox: <https://astriatx.com/index.html#for-patients>

For advocacy questions: advocacy@astriatx.com

Follow us on social media: [@AstriaTx](https://twitter.com/AstriaTx)

